Commonwealth Equity Services LLC Has $80.92 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Commonwealth Equity Services LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 364,473 shares of the medical research company’s stock after selling 15,067 shares during the quarter. Commonwealth Equity Services LLC owned 0.07% of Amgen worth $80,920,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in AMGN. Claro Advisors LLC increased its position in shares of Amgen by 6.9% during the 2nd quarter. Claro Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $415,000 after purchasing an additional 120 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its holdings in Amgen by 3.8% during the 2nd quarter. Tokio Marine Asset Management Co. Ltd. now owns 11,012 shares of the medical research company’s stock worth $2,445,000 after acquiring an additional 402 shares during the last quarter. Reuter James Wealth Management LLC grew its holdings in Amgen by 48.0% during the 2nd quarter. Reuter James Wealth Management LLC now owns 4,363 shares of the medical research company’s stock worth $969,000 after acquiring an additional 1,416 shares during the last quarter. Fortune Financial Advisors LLC bought a new stake in Amgen during the 2nd quarter worth about $230,000. Finally, FCA Corp TX grew its holdings in Amgen by 10.4% during the 1st quarter. FCA Corp TX now owns 17,321 shares of the medical research company’s stock worth $4,187,000 after acquiring an additional 1,634 shares during the last quarter. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Trading Down 1.3 %

Shares of NASDAQ:AMGN traded down $3.61 during mid-day trading on Friday, reaching $265.39. The stock had a trading volume of 2,642,931 shares, compared to its average volume of 2,476,674. The company has a current ratio of 2.86, a quick ratio of 2.56 and a debt-to-equity ratio of 7.71. The firm has a market cap of $142.03 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. The firm has a 50 day simple moving average of $269.59 and a two-hundred day simple moving average of $247.27. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $291.60.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 31st. The medical research company reported $4.96 EPS for the quarter, topping the consensus estimate of $4.65 by $0.31. The firm had revenue of $6.90 billion for the quarter, compared to the consensus estimate of $6.92 billion. Amgen had a net margin of 28.20% and a return on equity of 165.37%. The business’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the company posted $4.70 EPS. On average, research analysts predict that Amgen Inc. will post 18.65 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be issued a dividend of $2.13 per share. The ex-dividend date is Thursday, November 16th. This represents a $8.52 annualized dividend and a yield of 3.21%. Amgen’s dividend payout ratio (DPR) is currently 60.55%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research analyst reports. Oppenheimer increased their price objective on shares of Amgen from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Jefferies Financial Group reissued a “buy” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, October 12th. Truist Financial raised shares of Amgen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $260.00 to $320.00 in a report on Thursday, November 2nd. StockNews.com began coverage on shares of Amgen in a research note on Thursday, October 5th. They issued a “strong-buy” rating on the stock. Finally, Wells Fargo & Company raised their target price on shares of Amgen from $265.00 to $320.00 in a research note on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $278.15.

Insiders Place Their Bets

In related news, major shareholder Amgen Inc bought 1,764,705 shares of the company’s stock in a transaction on Tuesday, September 19th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $29,999,985.00. Following the acquisition, the insider now owns 35,368,653 shares of the company’s stock, valued at approximately $601,267,101. The purchase was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Jonathan P. Graham sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total value of $2,728,100.00. Following the sale, the executive vice president now owns 28,078 shares of the company’s stock, valued at $7,659,959.18. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Amgen Inc acquired 1,764,705 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $29,999,985.00. Following the transaction, the insider now owns 35,368,653 shares of the company’s stock, valued at $601,267,101. The disclosure for this purchase can be found here. Corporate insiders own 0.46% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.